Format

Send to:

Choose Destination
See comment in PubMed Commons below
ACS Chem Biol. 2013 Jul 19;8(7):1423-8. doi: 10.1021/cb4000629. Epub 2013 Apr 26.

Discovery of a selective irreversible BMX inhibitor for prostate cancer.

Author information

  • 1High Magnetic Field laboratory, Chinese Academy of Sciences , P.O. Box 1110, Hefei, Anhui 230031, P. R. China.

Abstract

BMX is a member of the TEC family of nonreceptor tyrosine kinases. We have used structure-based drug design in conjunction with kinome profiling to develop a potent, selective, and irreversible BMX kinase inhibitor, BMX-IN-1, which covalently modifies Cys496. BMX-IN-1 inhibits the proliferation of Tel-BMX-transformed Ba/F3 cells at two digit nanomolar concentrations but requires single digit micromolar concentrations to inhibit the proliferation of prostate cancer cell lines. Using a combinatorial kinase inhibitor screening strategy, we discovered that the allosteric Akt inhibitor, MK2206, is able to potentiate BMX inhibitor's antiproliferation efficacy against prostate cancer cells.

PMID:
23594111
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for American Chemical Society
    Loading ...
    Write to the Help Desk